DermaSensor

• ·DermaSensor’s last known valuation is $66.8M (Dec 2024).
• ·It has raised $66.7M across 2 recorded rounds; the latest was Early Stage VC ($8.9M) in Nov 2024.
• ·Notable investors include MedTech Innovator, Texas Medical Center, Ligo Partners, Lateral Capital Management, Miami Angels — 19 tracked in total.
• ·1 investment vehicle was formed to buy DermaSensor shares in the last 12 months, reporting $55K sold to 4 investors, per SEC Form D filings.
• ·DermaSensor has filed 2 Form Ds with the SEC since 2020, most recently Dec 2024 ($8.9M sold to 41 investors).
• ·Status: Privately Held (backing).

In the last 12 months, 1 investment vehicle were formed to buy DermaSensor shares, reporting $55K sold to 4 investors. Most recent filing Mar 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.

Developer of a skin cancer evaluation technology designed to provide spectroscopy and machine learning technologies to detect skin cancer early. The company's technology utilizes elastic scattering spectroscopy technology and machine learning algorithms to track and differentiate cancerous skin and send alerts and notifications when such cells are detected, enabling patients to efficiently check for skin cancer at home and clinics without waiting for time-consuming diagnostic reports.

Sector

Healthcare

HQ

Miami, FL, United States

Founded

2009

Employees

31

Website

dermasensor.com/

Ownership

Privately Held (backing)